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Abstract
Background:  RNA interference (RNAi) is a regulatory mechanism conserved in higher
eukaryotes. The RNAi pathway generates small interfering RNA (siRNA) or micro RNA (miRNA)
from either long double stranded stretches of RNA or RNA hairpins, respectively. The siRNA or
miRNA then guides an effector complex to a homologous sequence of mRNA and regulates
suppression of gene expression through one of several mechanisms. The suppression of gene
expression through these mechanisms serves to regulate endogenous gene expression and protect
the cell from foreign nucleic acids. There is growing evidence that many viruses have developed in
the context of RNAi and express either a suppressor of RNAi or their own viral miRNA.
Results: In this study we investigated the possibility that the HIV-1 TAR element, a hairpin
structure of ~50 nucleotides found at the 5' end of the HIV viral mRNA, is recognized by the RNAi
machinery and processed to yield a viral miRNA. We show that the protein Dicer, the enzyme
responsible for cleaving miRNA and siRNA from longer RNA sequences, is expressed in CD4+ T-
cells. Interestingly, the level of expression of Dicer in monocytes is sub-optimal, suggesting a
possible role for RNAi in maintaining latency in T-cells. Using a biotin labeled TAR element we
demonstrate that Dicer binds to this structure. We show that recombinant Dicer is capable of
cleaving the TAR element in vitro and that TAR derived miRNA is present in HIV-1 infected cell
lines and primary T-cell blasts. Finally, we show that a TAR derived miRNA is capable of regulating
viral gene expression and may be involved in repressing gene expression through transcriptional
silencing.
Conclusion: HIV-1 TAR element is processed by the Dicer enzyme to create a viral miRNA. This
viral miRNA is detectable in infected cells and appears to contribute to viral latency.
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Background
RNA interference (RNAi) is a regulatory mechanism
found in plants, nematodes, protozoan, Drosophila, and
mammalian cells [1-3]. Double stranded RNA is recog-
nized by the RNAi machinery and is processed into small,
21 nucleotide small-interfering RNA (siRNA) which are
capable of suppressing gene expression. Exogenously
introduced dsRNA is recognized by the cellular ribonucle-
ase III enzyme Dicer and cleaved into 21 nucleotide seg-
ments. Endogenously expressed RNA can be involved in
RNAi through a slightly different pathway involving Dro-
sha mediated cleavage of RNA stemloops in the nucleus,
followed by exportation to the cytoplasm by Exportin-5,
and finally cleavage by Dicer to generate a small RNA
duplex, called microRNA (miRNA) [4-9].
One strand of the miRNA duplex is incorporated into one
of two Argonaute containing effector complexes which
silence gene expression through two different mecha-
nisms. In the first, the small RNA associates with the RNA-
induced silencing complex (RISC) and guides the com-
plex to a complementary sequence of mRNA where a
member of the Argonaute family of proteins cleaves the
target mRNA [1-3,10]. Alternatively, the miRNA may
guide the RISC complex to a complementary, but not per-
fectly matching, region in the 3'UTR of the mRNA. This
association inhibits protein translation without degrading
the target mRNA [2,11,12]. Alternatively the RNA can
associate with the RNA-induced initiation of transcrip-
tional silencing (RITS) complex. The miRNA guides this
complex to a complementary region of chromosomal
DNA and recruits factors that modify the chromatin struc-
ture and induce transcriptional silencing [13-16].
The two pathways of RNAi likely serve several purposes.
Recognition of foreign RNA and subsequent processing by
RISC may serve as a defense mechanism against viral
infection [17]. RNAi may serve as a means for cells to
maintain specific chromosomal architecture and repress
transcription of retro-transposons [13,18,19]. Addition-
ally, it has been discovered that miRNA generated by the
cell is important for embryonic development and RNAi
may serve as a broad regulator of gene expression [20-23].
The structures of many viral RNAs likely provide appropri-
ate targets for the RNAi machinery. Several viruses have
already been identified that yield small RNAs after Dicer
processing, including; human cytomegalovirus, human
herpesevirus 8, Epstein Barr virus and peach latent mosaic
viroid [24-26]. Another group has reported that a miRNA
is produced from the Nef-RNA of HIV-1 [27]. Recent com-
puter modeling has also predicted the existence of up to
five structures in HIV-1 RNA that may be processed by
Dicer to yield miRNA [28,29]. Additionally, it has been
shown that a region within the Env gene contains a stem-
loop structure that is potentially acted upon by Dicer and
the components of RNAi [30].
If HIV-1 does produce RNA structures that are recognized
and cleaved by Dicer, then this could give rise to several
interesting possibilities that would be consistent with the
discovery that HIV downregulates many cellular genes
[31-33]. A viral miRNA generated from full-length, dou-
bly spliced or singly spliced HIV-1 transcripts could
potentially inhibit viral replication or down regulate cel-
lular gene expression. Dicer cleavage products of viral
RNA may target the RISC complex to degrade viral mRNA
or block translation of viral proteins, through sequence
complementarity. HIV miRNAs may associate with the
RITS complex and cause chromatin remodeling of the
viral genome, leading to transcriptional repression.
Indeed, the integrated HIV genome is associated with
chromatin remodeling complexes and recruitment of pro-
teins with histone acetyl-transferase activity that are
needed for proper activation of the virus [34-36]. And
finally, it may be possible that these miRNAs do not target
viral genes, but instead regulate the expression of cellular
proteins [28]. HIV infection has already been shown to
alter host gene expression through other mechanisms,
such as the viral proteins Tat, Nef and Vpr [31-33].
Therefore, suppression of viral replication or alteration of
host cell gene expression by viral miRNA may be a possi-
ble mechanism involved in latency. In latent cells there is
a low level of transcription and very little production of
viral proteins [37,38]. Due to this lack of transcription
there is a very low level of Tat protein available to recruit
various Cyclin/cdks and chromatin-remodelling factors
needed for activated transcription. As a result, latent cells
may produce a high level of short, abortive RNA tran-
scripts only 50–100 nt in length, that contain the HIV TAR
stemloop. To address this possibility, the Peterlin lab iso-
lated PBMCs from HIV-1 infected patients, analyzed the
transcriptional profile using RT-PCR, and found that in
some patients only short transcripts of less than 97 nucle-
otides were detectable [39,40]. Also, Lassen and Siliciano
purified resting CD4+ T-cells from HIV-1 patients and
showed the presence of short transcripts in both viremic
and non-viremic patients, with short transcripts being
more abundant than longer processive transcripts in the
non-viremic patients [41]. The HIV-1 TAR element is sim-
ilar to known dicer substrates, as it is an imperfect stem-
loop of approximately 50 nucleotides [42]. Additionally,
computer modeling has predicted TAR to be one of five
structures in HIV that is possibly processed by Dicer [28].
As these TAR-containing short transcripts are the only HIV
RNA produced in appreciable quantities during latency it
is possible that miRNAs generated from TAR may work to
suppress viral gene expression or alter host-cell proteins
levels, and in doing so, maintain the latent state.BMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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Further support of a role for TAR in RNAi stems from
recent findings that identify TAR-RNA Binding Protein
(TRBP) as the human homologue of the Drosophila Loqua-
cious protein [43,44]. Loquacious and TRBP are Dicer
binding partners that are required for efficient loading of
the miRNA into the RISC complex [43]. Interestingly,
TRBP was discovered over a decade ago through its associ-
ation with the TAR element and plays a role in transacti-
vation and inhibition of interferon induced PKR [45-48].
That other components of the RNAi pathway, such as
TRBP, can be found associated with the TAR element is
striking evidence that TAR may be processed to yield
miRNA.
Here, we show evidence that the short transcripts in
latently infected cells may lead to production of a viral
miRNA. We show that Dicer is expressed in CD4+ T-cell
lines and in primary cells isolated from healthy donors.
Interestingly, Dicer levels monocytic cell lines and pri-
mary cell was found to be sub-optimal. Using a biotin
labeled TAR RNA we show that Dicer, from whole cell
extracts, is capable of binding the TAR structure. This
interaction is specific and can be blocked by addition of
an unlabeled competitor but not by a mutant TAR. In vitro
transcribed TAR is cleaved by recombinant Dicer to yield
a 21 nucleotide RNA duplex. Analysis of a selection of TAR
mutants reveals that changes in the sequence of the TAR
structure have little effect on Dicer cleavage. Specifically
TAR mutants that are deficient for the Tat binding site or
the terminal loop are still cleaved by Dicer. Only one
mutant, which had a shortened stem, was incapable of
being processed by Dicer. Additionally, we show evidence
for existence of a HIV-1 TAR derived miRNA in HIV-1
infected cells through the use of an RNase protection assay
(RPA). This miRNA may be incorporated into the RISC or
the RITS complex and suppress either viral or cellular gene
expression.
Results
HIV-1 target cells express Dicer
As Dicer is the major catalytic engine that generates
miRNA through the cleavage of dsRNA, we sought to
determine if cell lines relevant to HIV-1 infection also
expressed Dicer. We tested cell extracts from CD4+ T-cell
lines (Hut78, Molt4, H9, Jurkat, CEM) and HIV-1 infected
CD4+ T-cell lines (J1.1, ACH2). Dicer expression was
detected in all of the T-cell types tested (Fig 1A). Normal-
ization to β-actin (Fig 1A, lower panel and ratios listed
below) revealed that the T-cell lines express similar levels
of Dicer, with the exception of Hut-78 cells that appear to
express about twice as much Dicer as the others (Compare
lane 1 to lanes 2–7). Interestingly, HIV-1 infection does
not appear to significantly influence Dicer expression
based on our analysis of Jurkat and CEM lines as com-
pared to their infected counterparts (compare lane 4 to 6
and 5 to 7). This suggests that Dicer is present in unin-
fected and HIV-1 infected cells. That Dicer is present sug-
gests that miRNA may be generated by these cell types.
These results confirm previous studies that have shown
production of miRNA, correlating with active Drosha and
Dicer enzymes, and an active RNAi system in T-lym-
phocytes [22,23,49,50].
We next sought to determine if Dicer is present in cells of
myeloid lineage. Monocytes (THP-1), pro-monocytes
(U937), HIV-1 infected pro-monocytes (U1) and infected
pro-myelocytes (OM10.1) were tested for Dicer expres-
sion (Fig 1B). With the exception of OM10.1 pro-myeloc-
tyes, none of the myeloid cells expressed levels of Dicer
visible by our western blots (Fig 1B, compare lanes 1–3 to
4). OM10.1 are a derivative of HL-60 that have survived
acute infection with HIV-1 [51]. HL-60 are a pro-myeloid
cell line capable of differentiating into basophils, neu-
trophils, eosinophils and monocytes. Butyric acid can spe-
cifically promote differentiation of these cells into
neutrophils [52,53]. The infection of OM10.1 represents
an artificial situation that allowed the study of CD4 levels
in response to infection [51]. That western blot could not
detect Dicer expression in monocytes, as compared to T-
cells, is interesting as CD4+ T-cells support latent infec-
tion in HIV, but monocytes and macrophages do not
[38,54]. The detectable Dicer expression in the pro-mye-
loid OM10.1, a pro-genitor of monocytes, cells is likely
related to Dicer's role in differentiation and development.
Previous studies have shown that the components of
RNAi are necessary for control of development and main-
tenance of pro-genitor cells [11,20,22,43]. Indeed, analy-
sis of miRNA expression patterns in differentiating HL-60
cells suggest an involvement of RNAi in differentiation
[55].
To verify these findings in a more relevant set of cells we
isolated PBMCs from healthy donors (Designated A, B, C,
D and E). After separation of PBMCs from whole blood
using ficoll, monocytes were separated from lymphocytes
(CD4+ T-cells, CD8+ T-cells and B-cells) by plastic adher-
ence. The lymphocytes, in the suspension fraction, were
removed from the plate, washed with PBS and lysed.
Monocytes that were adhered to the plate were washed
once with PBS to remove any remaining lymphocytes,
scraped from the plate and lysed. Twenty micrograms of
whole cell extract from monocytes and five micrograms
from lymphocytes was resolved by SDS-PAGE and west-
ern blotted for Dicer and β-actin. As expected, Western
blot analysis revealed that primary lymphocytes express
Dicer, but that Dicer levels in primary monocytes were
sub-optimal (Fig 1C, compare lanes 1–3 with 4–5). To
further examine expression of Dicer in monocytes addi-
tional western blotting and quantitative RT-PCR was per-
formed (Fig 1D and 1E). Decreasing amounts of CEMBMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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extract were used for western blot (Fig 1D, lanes 1–3)
showing detection of Dicer down to 5 micrograms of
extract. Western blotting 100 micrograms of U937 or U1
extract failed to detect Dicer (lanes 4 and 5). To confirm
these results cell lysates were prepared using a 7 M Urea, 2
M Thiourea buffer (lanes 6 and 7) or through loading
100,000 cells directly onto the gel after lysis in laemlii
buffer (lanes 8 and 9). These alternative methods of pro-
tein extraction should provide greater solubility of pro-
teins. However, these methods of lysis also yielded very
little detectable Dicer, even when 50 micrograms of
extract was loaded on the gel. Quantitative RT-PCR indi-
Dicer expression in HIV-1 infected and target cell-lines Figure 1
Dicer expression in HIV-1 infected and target cell-lines. A) Thirty micrograms of whole cell extract from CD4+ T-cell 
lines (lane 1 – Hut78, lane 2 – Molt 4, lane 3 – H9, lane 4 – Jurkat, lane 5 – CEM) and HIV-1 infected CD4+ T-cell lines (lane 6 
– J1.1, lane 7 – ACH2) was resolved by SDS-PAGE and western blotted for the presence of Dicer and β-actin. Asterisks indi-
cate the position of the 220, 45 and 30 kDa mass standards. Densitometry was performed and the ratio of Dicer to β-actin was 
determined and is shown below the western blot images. B) Thirty micrograms of whole cell extract from monocytes (lane 1 
– THP-1), pro-monocytes (lane 2 – U937), HIV-1 infected pro-monocytes (lane 3 – U1) and HIV-1 infect pro-myelocytes (lane 
4 – OM10.1) was resolved by SDS-PAGE and western blotted for the presence of Dicer and β-actin. C) Monocytes and lym-
phocytes were isolated from three normal donors (designated A, B, C, D and E) as described in materials and methods. Five 
micrograms of whole cell extract from lymphocytes and 20 micrograms from monocytes was resolved by SDS-PAGE and west-
ern blotted for the presence of Dicer. D) Decreasing amounts of CEM extract were western blotted for Dicer Lanes 1 – 20 
micrograms, 2 – 10 microgramsm 3 – 5 micrograms. 100 micrograms of U937 and U1 extract were blotted (lanes 4 and 5). 
Urea buffer was used to extract proteins from U937 and U1. Fifty micrograms of extract was western blotted for Dicer (lanes 
6 and 7). U937 and U1 cells were dissolved in Laemlii buffer for 2 minutes at 95° and loaded directly onto the gel (lanes 8 and 
9) E) Quantitative RT-PCR analysis was performed to examine the level of Dicer expression in CEM, ACH2, U937 and U1. 
Relative expression values were obtained by normalization to actin. F) U937 and THP-1 were cultured in the presence of 0, 
10, 20 or 100 nM PMA for 48 hours to induce differentiation. Twenty micrograms of whole cell extract from U937, THP-1, 
CEM, H9 and BJAB were resolved by SDS-PAGE and western blotted for Dicer. Densitometry was performed as in panel A.
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cates that Dicer mRNA is expressed in the CEM and ACH2
cell lines at comparable levels. Interestingly, Dicer mRNA
is detectable in U937 and U1 but at 40–60% less than the
levels in CEM and ACH2 (Fig 1E). These analyses suggest
that monocytes produce a level Dicer that may be sub-
optimal for Dicer driven cleavage of RNA, while T-cells
express high levels of Dicer.
To address the possibility that monocytes may express
Dicer upon differentiation to macrophages, U937 and
THP-1 cells were differentiated by treatment with 10, 20
or 100 uM phorbol-myristate acetate (PMA) for 48 hours
(Fig. 1F). Differentiation of U937 cells led to the produc-
tion of low levels of Dicer, however the level of Dicer
expression was 2–4 times lower than levels in T-cell lines
(compare lanes 2–4 to 9 and 10). This is in keeping with
work in the field that has used shRNA, which would
require Dicer cleavage, in macrophages [56,57].
These findings are interesting when considered in the con-
text of latent HIV infection, a phenomenon found in
CD4+ T-cells, but not in monocytes and macrophages
[38,54].
Dicer binds to the HIV-1 TAR stemloop
Several pieces of information suggest that Dicer may asso-
ciate with TAR RNA; Dicer is present in HIV-1 target cells,
TAR bears resemblance to known Dicer substrates, recent
computer modeling and the presence of a double-
stranded RNA binding domain in Dicer [28,58]. Associa-
tion of TAR containing transcripts with Dicer may lead to
the production of a TAR derived miRNA
In order to determine whether the HIV-1 TAR element is
recognized by Dicer we performed pull-down assays using
a biotin-labeled TAR. Biotin-labeled wild type TAR was
used to pull down the Dicer protein from 293, CEM,
ACH2 and BJAB cell lines. Dicer is detectable by western
blot after pull-down from each of the four cell types
tested, but not after incubation with streptavidin beads
alone (Fig 2A compare lanes 1–4 with 5–8). Comparison
of pull-down to the control lanes for CEM and 293 cells
reveals that incubation with biotin-TAR is capable of pull-
ing down 0.3–2.8% of the total cellular Dicer. Western
blotting of the biotin labeled TAR pull-downs revealed no
increase over background when staining for β-actin, indi-
cating a specific enrichment in TAR associated proteins
(data not shown). This shows that Dicer, expressed in
CD4+ T-cells and HIV-1 infected T-cells, binds to the HIV-
1 TAR structure and implies that the TAR element present
in HIV-1 infected or latently infected cells may be proc-
essed by Dicer to yield a viral miRNA.
To ascertain whether or not pulldown of Dicer by TAR is
specific to the structure of TAR, and not due merely to the
presence of RNA, we performed competition experiments
using unlabeled TAR and a TAR mutant. 293 cell extracts
were used for pulldowns to test the ability of wild type
and mutant TAR to compete with the biotin labeled TAR
for Dicer binding (Fig 2B). A TAR mutant, designated
TAR-D, was chosen that contains an extensively shortened
stem region, which we predicted would prevent Dicer
binding and processing (TAR-D sequence is shown in
Table 1, top panel, and in Fig 3B). Pull-downs were per-
formed as above, with the addition of two conditions
wherein 3.4 micrograms (a 2.4 fold excess) of either wild
type TAR or TAR-D (Fig 2B lanes 3 and 4 respectively) was
included during the incubation of extract with biotin
labeled TAR. Biotin-TAR associated proteins were pulled-
down by incubation with streptavidin beads and western
blotted for the presence of Dicer. Initial examinations of
the Western blot revealed that an unlabeled WT-TAR is
capable of competing with the biotin labeled TAR for
Dicer binding, while the TAR-D mutant does not. Densit-
ometry was performed to determine the relative amount
of Dicer present after each pulldown as compared to the
positive control (lane 2). Incubation with unlabeled wild
type TAR decreased the amount of Dicer detectable after
the pulldown to 16% of the positive control, or just above
background (Fig 2B, lane 3). Incubation with TAR-D had
no effect on the ability of biotin labeled TAR to pulldown
Dicer from whole cell extracts (lane 4).
To further verify the specificity of Dicer binding to the
wild type TAR structure and not the TAR-D mutant the
pulldown was repeated using a biotin labeled poly-U (Fig
3C). One milligram of 293 extract was incubated with no
RNA (lane 2), a 52 nucleotide biotin-poly-U RNA (lane
3), biotin labeled wild type TAR (lane 4), or a biotin
labeled TAR-D mutant (lane 5). The poly-U RNA, which
lacks extensive secondary structure, was incapable of
binding to Dicer. TAR-D was capable of binding Dicer, but
much less efficiently than the wild type (37% to 100%).
As TAR-D was incapable of competing with TAR-WT for
binding (Fig 2B), we believe that Dicer is not binding
directly to this mutant. TAR-D contains a high affinity
binding site for TRBP, between the pyrmidine bulge and
the terminal loop [45,46,59]. As TRBP is the cellular bind-
ing partner of Dicer, this association may allow TAR-D to
pulldown Dicer that is associated with TRBP [43,44].
Therefore, these experiments demonstrate, for the first
time, that the Dicer protein can bind to the HIV-1 TAR ele-
ment. Also, the competition experiments show that this
association of Dicer and TAR is specific to the TAR
sequence and cannot be disrupted by the addition of a
mutant that has a portion of the TAR stem deleted.BMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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Dicer cleaves the HIV-1 TAR stemloop, but not stemloop 
mutants
To test the ability of the TAR element to be cleaved by
Dicer, we incubated in vitro transcribed TAR with a recom-
binant Dicer and used ethidium bromide staining to
detect cleavage products on a 6% TBE-Urea polyacryla-
mide gel. Incubation of WT-TAR with Dicer yielded an
RNA fragment of approximately 21 nucleotides, which
was not present in samples incubated with a heat inacti-
vated Dicer, indicating that the small fragment was a Dicer
generated miRNA (Fig 3A, compare lane 4 to 5). The rela-
tive density of the 21 nucleotide fragment in lanes 2
through 5 was determined as compared to background in
the control lanes. An increase of approximately 5 fold over
background is seen in the lane with the Dicer digested
TAR. This level of cleavage was consistent across three sep-
arate experiments. Various titrations for the concentration
of NaCl and MgCl2 in the digestion buffer provided with
the recombinant Dicer did not result in any increase in
cleavage of TAR RNA (data not shown). This incomplete
in vitro cleavage, even under optimal conditions, appears
to be consistent with other studies that have evaluated the
conditions for optimal Dicer activity [60].
In an attempt to provide greater resolution of the Dicer
cleavage product, and obtain greater accuracy as to the size
of the product, the cleavage of TAR-WT was repeated using
a radio-labeled RNA substrate (Fig 3B). After digestion,
the resulting bands were separated on a 15% TBE-Urea gel
and visualized by autoradiography. This analysis allowed
the use of a small RNA marker, and shows that the cleav-
age product is running at approximately 21 nucleotides.
However, the overall resolution of this gel is not as sharp
as the ethidium bromide stained poly-acrylamide.
A panel of TAR mutants (Fig 3C), that have previously
been used to evaluate the importance of TAR, was also
tested for the ability to be cleaved by Dicer [61-64]. The
TAR-A mutant, which contains inversions of each base
pair in the stem, the TAR-B mutant, which contains no
pyrmidine bulge and TAR-C, with mutations in the termi-
nal loop are all processed by Dicer to yield a small RNA
product of approximately 21 nucleotides (Fig 3D, lanes
2–7 and 10–11). Densitometry was performed to com-
pare the intensity of the miRNA product band to back-
ground. In mutants A, B, and E this product band was
measured as an increase over background of 30, 4, and 11-
fold respectively. This increase correlates to the one seen
in Dicer processing of the wild type TAR RNA. The short
TAR-D mutant was not cleaved by Dicer (compare lane 8
to 9). Incubation of TAR-D with Dicer did not produce
any detectable 21 nucleotide fragments. Mutations in the
sequence of TAR that maintained the overall integrity of
the stemloop are still processed by Dicer. Significant
shortening of the stem beyond 20 nucleotides, as with
TAR-D, alleviates the ability of Dicer to catalyze cleavage
of the RNA. Collectively, these results suggest that Dicer
requires a stretch of dsRNA of approximately twenty
nucleotides to have an effect, a finding that is consistent
with other studies on Dicer activity [42,58]. The need for
a 20 nucleotide stretch of dsRNA likely explains why TAR-
D, which contains a stem of only 11 bases in length, was
not cleaved in our assays.
The TAR-E mutant provided an unexpected result. At first
we predicted that this mutant would not be cleaved by
Dicer due to its shortened size. However, repeated experi-
ments have shown that it is, in fact, cleaved by Dicer. We
believe this to be occurring for one of three possible rea-
sons; 1) the double-stranded portion of TAR-E is actually
Cellular Dicer associates with the HIV-1 TAR stem and loop  structure Figure 2
Cellular Dicer associates with the HIV-1 TAR stem 
and loop structure. A) Biotin labeled TAR-RNA was incu-
bated with one milligram whole cell extracts from 293, CEM, 
ACH2 and BJAB (lanes 1–4), pulled down with streptavidin 
beads, washed thrice with TNE-150, resolved by SDS-PAGE 
and detected for Dicer by western blot. One milligram cell 
extract incubated without biotin-TAR was used as a control 
(lanes 5–8) and 30 microgram whole cell extract from 293 
and CEM cells were included in the western as a positive 
control for Dicer detection (lanes 9 and 10). B) Unlabeled 
wild type (TAR-WT) and mutant TAR (TAR-D) were used in 
a competition experiment to examine the specificity of Dicer 
binding to TAR. 293 cell extracts were incubated in the pres-
ence (lane 1,3,4) or absence (lane 2) of 1.5 micrograms of 
biotin-labeled TAR. A 2.4 fold excess of TAR-WT (lane 3) or 
TAR-D (lane 4) was incubated with two of the samples. 
Biotin-TAR was pulled down with streptavidin beads and 
detected for Dicer by western blot as in panel A. Densitome-
try was performed to determine the relative amount of 
Dicer present after the pulldown, as compared to the posi-
tive control (lane 2). C) Pulldown was performed as in panel 
A, but included a biotin-PolyU and TAR-D in addition to the 
WT-TAR. Percentages indicate the relative pulldown as com-
pared to TAR-WT.
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2 bases longer than that of TAR-D and could perhaps alter
Dicer's ability to bind, 2) The long 5' tail may somehow
facilitate Dicer binding, 3) TAR-E may actually fold differ-
ently than predicted and form a longer hairpin. In support
of the third possibility we have predicted what TAR-E
would look like when the instability created by unpaired
stretches of RNA is considered (Fig 3B, TAR-E Alt). This
structure consists of two closely connected stem loops,
which now provide the short 3' overhang favored by Dicer
and increased the overall double-stranded character of the
structure. This alternative structure may facilitate Dicer
binding and cleavage.
HIV-1 positive cell lines produce a TAR derived miRNA
In order to ascertain whether or not HIV-1 infected cells
produce a TAR derived miRNA, we utilized RPA to detect
small RNA fragments corresponding to TAR sequence.
Probes were designed which were complementary to the
entire length of the 5' or 3' portion of the TAR stem loop
and would detect the generation of ~21 nt RNAs from any
position (Table 1 and Fig 4A).
Initially we sought to detect the presence of a TAR derived
miRNA in the ACH2 cell line. ACH2 are chronically
infected CD4+ T-cells, which produce virus at low levels
but can be stimulated to high levels of virus production
with TNF-α, sodium butyrate or trichostatin-A. Thirty
micrograms of total RNA from ACH2 was probed for TAR
derived miRNA by RPA using the TAR 5' probe or 3' probe
(Fig 4B). RNase protection assay revealed the presence of
an HIV-1 derived miRNA in ACH2 corresponding to the 5'
(lane 4) but not the 3' portion of TAR (Data not shown).
Detection of only one strand of the duplex is consistent
with the current understanding of miRNA biogenesis.
After the cleavage of double stranded RNA by Dicer one
strand of the 21 nucleotide duplex is guided by Dicer and
TRBP into the RISC complex to become the guide strand.
The other strand is degraded, likely through the action of
RISC [65-68]. The presence of a TAR derived miRNA in
ACH2 cells was also supported by northern blot analysis
(data not shown).
We sought to assay the presence of TAR derived miRNA in
several cell types. As we hypothesize that a TAR generated
miRNA may be involved in viral latency, we sought to test
cell lines that would serve as a cell culture model of
latency. We chose cell lines that are infected with HIV-1,
produce a low or undetectable level of virus, and can be
stimulated to produce high levels of infectious virus. We
selected ACH2 again as a control. For cells of myeloid lin-
eage, we selected the chronically infected OM10.1 pro-
myelocytic cells; the only cells of the monocyte lineage in
Table 1: Sequence of HIV-1 TAR, TAR mutants, oligonucleotides used to generate RPA probes, and synthetic siRNA
Name Sequence
TAR-WT GGUCUCUCUGGUUAGACCAGAUCUGAGCCUGGGAGCUCUCUGGCUAACUAGGGAACC
TAR-A GCACAGGGAUCAAUCAGGUCUUCUCUCGCUGGGACGAGAGACCGAUUGGUCUCUUGC
TAR-B GGUCUCUCUGGUUAGACCAGA___GAGCCUGGGAGCUCUCUGGCUAACUAGGGAACC
TAR-C GGUCUCUCUGGUUAGACCAGAUCUGAGCCU___AGCUCUCUGGCUAACUAGGGAACC
TAR-D GG______________CCAGAUCUGAGCCUGGGAGCUCUCUGG____________CC
TAR-E GGUCUCUCUGGUUAGACCAGAUCUGAGCCUGGGAGCUCUCUGGCUA___________
T7 Primer TAATACGACTCACTATAGGGAGA
TAR 5' Template GGTCTCTCTGGTTAGACCAGATCTGATTTTTTCTCCCTATAGTGAGTCGTATTA
TAR 3' Template AGCTCTCTGGCTAACTAGGGAACCCACTTTTTTCTCCCTATAGTGAGTCGTATTA
siGL2 5' CGUACGCGGAAUACUUCGAUU 3'
3' UUGGAUGCGCCUUAUGAAGCU 5'
siGFP 5' GCGACGUAAACGGCCACAAGUUCUC 3'
3' GCCGCUGCAUUUGCCGGUGUUCAAG 5'
siTAR1 5' UGGGUCUCUCUGGUUAGACCAGUU 3'
3' UUACCCAGAGAGACCAAUCUGGUC-P 5'
siTAR2 5' CUCUCUGGCUAACUAGGGAACCUU 3'
3' UUGAGAGACCGAUUGAUCCCUUGG-P 5'
LTR forward CGAGCTTGCTACAAGGGACT
LTR reverse GAGATTTTCCACACTGACTAAAAGG
Luc forward TGAACTTCCCGCCGCCGTTGT
Luc reverse TTACAATTTGAACTTTCCGCC
DicerRT F TTTGTGCAGTTTCAGCTTGA
DicerRT R CCATGGCCTTTGGAACTTCBMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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which we detected Dicer expression. These cells are
latently infected and can be stimulated, much like ACH2,
to produce high levels of full-length transcript and infec-
tious virus. Finally, we chose HLM-1, a HeLa derivative
that is stably transfected with an HIV-1 provirus and is
wildtype for all ORFs except Tat. Much like the OM10.1
and ACH2, the HLM-1 cells produce no detectable virus
but can be stimulated with TNF-α, sodium butyrate, tri-
chostatin-A or Tat to produce infectious virus.
Thirty micrograms of total RNA from either unstimulated
HLM-1, ACH2, OM10.1 or cells stimulated for 24 hours
Dicer cleaves the HIV-1 TAR structure in vitro Figure 3
Dicer cleaves the HIV-1 TAR structure in vitro. A) In vitro transcribed HIV-1 TAR was incubated overnight in the pres-
ence of recombinant Dicer or heat-inactived (95° for two minutes) recombinant Dicer, separated on a 6% TBE-UREA gel and 
stained with ethidium bromide. A 100 bp DNA ladder (lane 1 – band visible at the top of the gel corresponds to 100 bp) and 
commercially available siRNA against siEGFP (lane 2) were included as size standards. Lane 3 – one microgram in vitro tran-
scribed TAR. Lane 4 – one microgram TAR incubated with rDicer. Lane 5 – one microgram TAR incubated with heat inacti-
vated Dicer. Arrow indicates the ~21 nt band generated by Dicer cleavage. Densitometry indicates the signal in the 21 nt 
region of the gel relative to undigested TAR. B) Digest was repeated as in panel A. Products were resolved on a 15% TBE-
Urea gel and visualized by autoradiography. MW (lane 1) was exposed for 5 minutes, while the digests (lanes 2–4) were 
exposed for 2 hours. Numbers to the left indicate the size of the associated RNA marker. C) Predicted structures of the TAR 
mutants used for Dicer cleavage analysis. TAR-A is a compensatory mutant, where the base pairs in the stem have been 
switched. TAR-B has the bulge (TAR binding site) deleted. TAR-C has a deletion in the terminal loop. TAR-D has a truncated 
stem. TAR-E has a shortened stem and a long 5' tail, or may fold into a two looped structure. D) TAR mutants pictured in 
panel B were digested with Dicer, separated on a TBE-UREA gel and stained with ethidium bromide. Lane 1 – 100 bp marker. 
Pictured are mutants TAR elements before and after Dicer treatment; TAR-A (lanes 2 and 3), TAR-B (lanes 4 and 5), TAR-C 
(lanes 6 and 7) and TAR-D (lanes 8 and 9). Densitometry was performed as in panel A, where the intensity of the 21 nt region 
of the gel is shown in relation to the undigested mutant.
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with 450 nM Trichostatin-A was probed for TAR derived
miRNA by RPA using the TAR 5' probe. RNase protection
assay revealed the presence of an HIV-1 derived miRNA
corresponding to the 5' portion of TAR in ACH2, OM10.1
and HLM-1 cells (Fig 4C, lanes 5–7). Densitometry was
performed to determine the relative levels of the TAR
miRNA in each cell type. Stimulation of these cells with
trichostatin-A, which induces high levels of HIV-1 expres-
sion, resulted in an increase in expression of this miRNA
in ACH2 and OM10.1 by 2.8 and 1.5 fold respectively (Fig
4A, compare lanes 5 and 6 to 8 and 9). Additionally, this
second analysis allowed us to resolve two bands in the
HIV-1 infected T-cell lines produce a miRNA derived from the TAR element Figure 4
HIV-1 infected T-cell lines produce a miRNA derived from the TAR element. A) Graphical representation of what 
region of TAR is detected by the probe the probe used for RPA. TAR 5' probe detects sequence from the 5' area of the stem 
(~30 bases), while TAR 3' detects the 3' side of the stem. B) Thirty micrograms of total RNA from ACH2 was hybridized to a 
radiolabeled RNA probe specific for 5' (lanes 3 and 4) region of the TAR stem loop and then treated with RNase A and T1. As 
a control the probes were incubated alone with RNase A and T1 (lanes 3). Molecular weight marker corresponding to 20 
nucleotides is shown (lane 1) as well as a 22 nucleotide standard (lane 2). C) Thirty micrograms of total RNA from THP-1, 
CEM, OM10.1, (lanes 3 and 4) ACH2, OM10.1 and HLM-1 (lanes 5–7) and from OM10.1, ACH2 and HLM-1 stimulated with 
TSA for 24 hours (lanes 8–10) were hybridized to a radiolabeled TAR 5' probe and then treated with RNase A and T1. As a 
control probe was incubated alone with RNase A and T1 (lane 2). Molecular weight markers corresponding to 20 and 30 
nucleotides are shown (lane 1). Arrows indicate the probe protected by TAR at 27 nucleotides and probe protected by a TAR 
miRNA at approximately 22. D) T-cell blasts were cultured from PBMCs using IL-2 and PHA for 48 hours. T-cells were 
infected with HIV-1 (LAV) and cultured in RPMI with IL-2 for 6, 12 and 18 days. RNA from uninfected cells at day 6, 12 and 18 
(8.3, 3.7 and 16.8 micrograms respectively – lanes 4–6) and infected cells at 6,12 and 18 (9.2, 16.5 and 22.9 micrograms – lanes 
7–9) was probed for presence of TAR derived miRNA using the 5'TAR probe. A sample containing no RNA was included as an 
additional negative control as were 15 and 30 micrograms of ACH2 RNA (lanes 1–3). E) HLM-1 cells were transfected with 
siLuc or siDicer for 72 hours. RNA extract was used to perform RPA for HIV-1 miRNA. F) Expression of HIV-1 TAR miRNA 
was determined by densitometry and normalized to 5S ribosomal RNA.
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RPA. The top band migrates at approximately 27 nucle-
otides and represents probe protected by full-length TAR,
while the lower band migrates at 22 nucleotides and rep-
resents probe protected by hybridization to a TAR-derived
miRNA. Knowing that our RPA was capable of detecting
full length TAR and the miRNA, we wondered why our
probing of ACH2 with TAR3' did not reveal a full length
TAR product (Fig 4B). We believe this lack of detectable
product is due to a previously characterized mutation
within the TAR element of the ACH2 cell line [69]. This
mutation falls within the area probed by TAR3' and would
lead to loss of protection and subsequent degradation of
the probe by RNase.
To examine the presence of TAR derived miRNA in de novo
infection of T-cell blasts from a healthy donor, PBMCs
were infected with HIV-1 and grown in culture for 18
days. RNA was harvested from infected and uninfected
cells at days 6, 12 and 18. RNA extracts from these time
points were analyzed by RPA for the presence of the TAR
derived miRNA detected in panels B and C (Fig. 4D). RPA
revealed the presence of a 22 nucleotide miRNA in the day
6 and 12 infection, but not in the uninfected cells (com-
pare labes 4 and 5 to 7 and 8). Interestingly, on day 6 the
ratio of TAR to miRNA is about equal, whereas on day 12
the majority species is the miRNA. This suggests that pro-
duction of the TAR derived miRNA may continue, even as
viral transcription is reaching its peak and ending. We
were unable to detect either TAR or TAR miRNA on day
18, likely due to the limited life span of infected T-cell
blasts in culture.
To confirm that the 22 nucleotide RNA product is indeed
a miRNA yielded by Dicer acting upon the TAR element
we knocked-down the expression of the Dicer protein in
HLM-1. HLM-1 were transfected with siDicer (Dhar-
macon) or a control siRNA against Luciferase (siLuc) and
cultured for 72 hours. RNA was prepared from HLM-1 at
72 hours post transfection and used for RPA analysis of
miRNA expression (Fig 4E). Expression of TAR derived
miRNA was measured by densitometry and normalized to
signal from the 5S ribosomal RNA (Fig 4F). Analysis
revealed that knockdown of Dicer expression for 72 hours
reduced the level of TAR miRNA expression by approxi-
mately 75%. This indicates that the 22 nucleotide band
detected by RPA is indeed a Dicer generated miRNA.
These RPA analyses present evidence that the HIV-1 TAR
structure is processed into miRNA in vivo. This TAR
derived miRNA can be detected in latently infected cell
lines and stimulation of these cells line increases miRNA
expression by approximately two-fold. Additionally, this
miRNA can be detected in acute infection of primary T-
cells.
siRNA directed against the HIV-1 LTR down regulates LTR 
driven gene expression
A miRNA generated from one side of the HIV TAR stem-
loop, such as the small RNA detected by the TAR 5' probe
in our RPA assay, will possess significant similarity to the
complementary strand of the TAR element. Production of
this viral miRNA may down regulate viral gene expression
by targeting the RISC or RITS complexes to viral RNA tran-
scripts that contain the TAR element.
The target region for our proposed miRNA lies within the
secondary structure of TAR. As previous reports have indi-
cated that extensive secondary structure may prevent
access of RISC to the mRNA and render the sequence less
susceptible to RNAi mediated down-regulation [70,71],
we sought to determine if HIV-1 TAR is susceptible to reg-
ulation by RNAi.
We tested the ability of TAR derived miRNA to downregu-
late viral gene expression through the use of a plasmid
containing the luciferase gene under control of the HIV-1
LTR. Transcription initiated by the viral LTR will produce
a luciferase mRNA with the TAR structure at the 5' end.
Transfection of in vitro transcribed TAR RNA into a Dicer
producing cell should allow processing of the TAR stem-
loop by cellular Dicer and generate the same miRNA
detected in our Dicer cleavage assays. As such, we trans-
fected 293 cells in a 96-well plate with 100 nanograms of
pLTR-Luc, 100 nanograms of pRL-CMV and 25 nano-
grams of RNA. Cells were transfected with either in vitro
transcribed wild type TAR (TAR-WT), TAR mutant D or A
(TAR-D or TAR-A). TAR-D was selected as this mutant did
not yield a miRNA fragment after incubation with Dicer in
our Dicer cleavage assay and was incapable of competing
with wild type TAR for Dicer binding. TAR-A was selected
as the large sequence variations in the stemloop would
lead to production of a miRNA incapable of targeting an
RNAi effector complex to native TAR sequence. The firefly
Luciferase specific siGL2 was included as a control and the
amount of siRNA in each well was adjusted to 25 nano-
grams with siGFP, an siRNA against enhanced green fluo-
rescent protein, which serves as a negative control in these
experiments (siRNA sequences are depicted in Table 1).
Transfection efficiency was normalized by transfecting a
renilla luciferase under control of the CMV promoter
along with the LTR constructs. Data presented represents
the ratio of LTR driven expression to CMV driven expres-
sion, allowing specific determination of the effect of vari-
ous RNAs on the LTR constructs.
Wild type TAR RNA was capable of suppressing Luciferase
expression as compared to siEGFP (Fig 5). Luciferase spe-
cific siRNA (siGL2) induced a ~95% decrease in luciferase
activity as compared to control. TAR-WT suppressed luci-
ferase expression by ~60% at the 5 nanogram level andBMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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80% at the 25 nanogram level. Transfection of the TAR
mutants TAR-D and TAR-A had no significant effect on
luciferase activity. These results indicate that delivery of
wild type TAR RNA into cells decreases expression of a
protein driven by the HIV-1 LTR. This effect is likely due
to processing of TAR element by Dicer and incorporation
of the resulting miRNA into the RISC or RITS complex.
To further clarify whether TAR is available for regulation
by RNAi, we tested the ability of TAR specific siRNAs
(obtained from Dharmacon) to block LTR driven tran-
scription of luciferase. These TAR specific siRNAs have a 5'
phosphate on the antisense strand, which should enhance
incorporation of the antisense strand into the RISC com-
plex. This directs siTAR1 to specifically target the first half
(5') of the TAR element and siTAR2 to target the second
(3') half (indicated by underline in Table 1, top panel).
Delivery of siTAR1 or siTAR2 into 293 cells led to a sup-
pression of LTR-driven luciferase activity. Transfection of
5 nanograms of siRNA resulted in a 75% loss of luciferase
activity, while transfection of 25 nanograms of siRNA
resulted in only a slight improvement in suppression of
the lower concentration. The 75% suppression at 5 nano-
grams is greater than the 60% suppression triggered by
transfection of TAR-WT RNA, suggesting that the siTAR1 is
slightly more efficient at mediating suppression than the
in vitro transcribed TAR.
It should be noted that the luciferase specific siRNA is tar-
geted against the middle of the luciferase mRNA, an area
that likely does not contain extensive secondary structure
like the TAR element. The absence of secondary structure
in the target region for siGL2 may explain the fact that
TAR-WT RNA as well as siTAR1 and siTAR2 are incapable
of suppressing luciferase expression to the same level as
siGL2. This data shows that RNAi can be directed against
the TAR element, in spite of its extensive secondary struc-
ture. The HIV-1 TAR derived miRNA detected in the RPA
is derived from the first half of the TAR structure and is
complementary to the later half of TAR, much like the
siTAR2. These findings suggest that the TAR derived viral
miRNA detected in ACH2, OM10.1 and HLM-1 cells
could potentially be down regulating viral replication and
contributing to the low level of viral gene expression seen
in these cells. Although the induction of virus in these cell
types with TSA altered the production of viral miRNA dif-
ferently in each cell type, when considering that transacti-
vation by Tat increases viral transcription several-hundred
fold; it is likely that the increase in overall transcription
overcomes any blockage due to RNAi [72-74].
TAR derived miRNA causes HDAC-1 to associate with the 
viral LTR
Recent studies have shown that siRNA targeted to the NF-
κB sites within the viral LTR leads to transcriptional silenc-
ing through chromatin remodeling [75]. Additionally it
has been suggested that a TAR derived miRNA may have
similar effects [76]. To test the ability of a TAR derived
miRNA to direct chromatin remodeling at the viral LTR we
used chromatin immunoprecipitation to examine the
recruitment of HDAC-1, a histone deacetylase shown to
be involved in silencing of HIV, to the LTR of the pLTR-luc
plasmid [77].
293 cells were transfected with pLTR-Luc and either
siEGFP or TAR-WT RNA. Following crosslinking, lysis and
shearing of DNA by sonication, lysates were immunopre-
cipitated with an antibody against HDAC-1. Association
of HDAC-1 with either LTR or luciferase DNA was deter-
mined by PCR (Fig. 6A). Primers were designed to detect
the region surrounding transcription start (-119 to +175)
and an area ~2000 bases downstream of the transcription
site in the luciferase ORF. ChIPed DNA was diluted 1:20
and subjected to PCR for LTR sequence (panel A top
panel). Comparison of siTAR-1 transfection to siEGFP
control suggests that siTAR-1 RNA is capable of driving
HDAC recruitment at the LTR. Control analyses for unre-
lated antibody and input were also performed (second
and third panels). To examine the level of HDAC-1
recruitment downstream of the LTR PCR was performed
using luciferase specific primers (Fig 6A bottom two pan-
els). This analysis showed that no recruitment of HDAC-1
could be detected 2000 bases downstream from the
siRNA directed against the HIV-1 TAR structure can poten- tially downregulate LTR-driven viral expression Figure 5
siRNA directed against the HIV-1 TAR structure can 
potentially downregulate LTR-driven viral expres-
sion. 293 cells were transfected with 100 nanograms of 
pLTR-Luc, 100 nanograms of pRL-CMV and 25 nanograms of 
RNA and assayed 48 hours later for firefly and renilla luci-
ferase expression. Cells were transfected with 25 nanograms 
siGFP, 25 nanograms siGL2, 5 and 25 nanograms of TAR-
WT, TAR-D, TAR-A, siTAR1 or siTAR2. RNA levels were 
normalized to 25 nanograms using siGFP.
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miRNA target site. This suggests specific recruitment of
HDAC-1 to the promoter region complementary to the
TAR miRNA or synthetic siRNA.
To further verify the involvement of TAR derived miRNA
in chromatin remodeling we sought to test its effects on
an integrated HIV-1 LTR. For this we utilized TZMbl cells,
a HeLa derivative that carries two integrated copies of the
HIV-1 LTR; one driving luciferase and the other driving
beta-galactosidase. These cells express low levels of luci-
ferase in the absence of stimulation, suggesting that the
LTR is already silenced. Previous work in the field has
shown that chronic treatment of HeLa cells with the
HDAC inhibitor TSA abolishes the heterochromatic state
[78]. Indeed, a similar approach has been used to study
chromatin in yeast and elucidate the involvement of RNAi
[79,80]. As such we treated the cells for seven days with
the HDAC inhibitor TSA. This treatment induced detecta-
ble levels of luciferase gene expression, which began to
return to pre-treatment levels after the removal of TSA
(data not shown). This suggested to us that after the
removal of TSA the DNA was returning to the heterochro-
matic state and silencing gene expression.
We employed this system to analyze the effect of TAR and
siTAR1 on HDAC-1 recruitment to the integrated HIV-1
LTR. TZMbl cells were treated with 100 nM TSA for 7 days.
On day 6 the cells were transfected with either TAR-WT,
siTAR1 or and siGFP control. On day 7 TSA was removed,
and on Day 8 cells were ChIPed for HDAC-1 or no anti-
body control (Fig 6B). Before treatment HDAC-1 was
associated with the LTR and this association was lost upon
treatment with TSA (compare lanes 1 and 2, top panel).
Transfection of the cells with TAR-WT or siTAR1 RNA led
to an increase in the recovery after 24 hours as compared
to the control (compare lane 3 to 4 and 5, top panel).
Control transfection with siGFP resulted in a level of
HDAC-1 recruitment similar to the untransfected cells
(compare lane 6 to 3). PCR using no-antibody ChIP and
input DNA showed comparable detection of LTR DNA in
all lanes (middle and bottom panels). Densitometry was
performed to analyze the relative levels of HDAC-1
recruitment to the integrated LTR (Fig 6C). Background
signal in the no antibody lanes was subtracted from the
HDAC-1 signal and displayed as a percentage of HDAC-1
on the LTR at day 0. This analysis revealed a 97% drop in
HDAC-1 association with the LTR after TSA treatment
(100% to 2.9%). Twenty four hour recovery, or transfec-
tion with siGFP, resulted in a slight reconstitution of
HDAC-1 (1.6% and 6.0% respectively), while transfection
of cells with TAR or siTAR1 greatly accelerated the recruit-
ment of HDAC-1 to the LTR (18.8% and 54.8% respec-
tively). Analysis of HDAC-1 recruitment to an integrated
LTR verifies that heterochromatin formation at the HIV-1
LTR is driven by RNA interference mediated by the TAR
derived miRNA. This effect is specific to the transfection of
an siRNA homologous to TAR sequence or to the TAR
hairpin, and is not seen with the control transfection.
The de-acetylation of histones by members of the HDAC
family is a key step in the formation of heterochromatin.
Modifications of the histone tails leads to condensation of
the chromatin structure and silencing of transcription at
the affected locus [81]. RNAi has been shown to be capa-
ble of silencing transcription through the RITS complex by
recruiting chromatin remodeling factors to a complimen-
tary sequence of DNA [13,14,16]. The recruitment of
HDAC-1 to the HIV-1 LTR in presence of either TAR spe-
cific siRNA or TAR RNA demonstrates that HIV-1 derived
miRNA is capable of silencing gene expression through
transcriptional gene silencing. The lack of HDAC-1 in the
luciferase ORF, approximately 2000 bases downstream,
demonstrates the specificity of this recruitment to the
complementary sequence in the LTR.
HDAC-1 is recruited to the HIV-1 LTR by TAR derived  miRNA Figure 6
HDAC-1 is recruited to the HIV-1 LTR by TAR 
derived miRNA. 293 cells were transfected with pLTR-Luc 
and either siGFP or siTAR1. After 48 hours cells were 
crosslinked with formaldehyde, lysed, sonicated and immu-
noprecipitated for HDAC-1 or a IgG antibody. A) PCR on 
DNA from HDAC-1 ChIP, control IgG ChIP and input was 
performed for either LTR or luciferase (Luc) region. B) 
TZMbl cells were cultured in the presence of 100 nM TSA 
for 0 or 7 days (lanes 1 and 2), and then allowed to recover 
in the absence of TSA withouth (lane 3), with either TAR-
WT or siTAR1 transfection (lanes 4 and 5), or transfection 
with siGFP (lane 6). PCR for LTR was performed on HDAC-
1 ChIP DNA (top panel), no antibody control (middle panel) 
or input DNA (bottom panel). C) Densitometry was per-
formed on the gel shown in panel B. Background signal in the 
no antibody PCR was subtracted from the HDAC-1 ChIP 
and results are shown as a percentage of HDAC-1 associa-
tion with the LTR before TSA treatment.
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Discussion
RNAi is a recently discovered regulatory mechanism, the
specificity of which is guided by small RNA molecules that
direct a silencing complex to a complementary sequence
of mRNA [1,3,82]. Based upon the precursor from which
these RNAs are derived they are termed siRNA or miRNA.
siRNA is generated from a long sequence of double
stranded RNA that is processed by a cellular ribonuclease
III enzyme called Dicer. miRNA is generated from endog-
enously expressed RNA that folds into a hairpin structure.
This hairpin is cleaved in the nucleus by an enzyme called
Drosha, exported to the cytoplasm and processed by Dicer
[2,4,7,9,83]. As the final processing step in the generation
of siRNA and miRNA is catalyzed by Dicer the final prod-
ucts cannot be differentiated. Each is a short double
stranded segment of RNA of approximately 21 nucle-
otides. Of this 21 nucleotide duplex, one strand is incor-
porated into an effecter complex and targets that complex
to a complementary sequence of RNA. RNAi may act post-
transcriptionally, by cleaving mRNA or repressing transla-
tion, or at the transcriptional level by initiating chromain
remodeling and silencing of Pol II mediated gene tran-
scription [1,2,16,82,84].
Although extensive attention has been given to the thera-
peutic applications of RNAi in the treatment of HIV, rela-
tively little work has been done to examine whether the
virus itself may generate miRNA or otherwise subvert the
RNAi mechanism for its own benefit [56,57,70,75,85-92].
The sequence specificity of RNAi provides us with a pow-
erful tool for examination of gene function and the poten-
tial to combat human diseases, but it should be noted that
it represents a natural pathway that has developed as a
means to regulate gene expression, protect the integrity of
the genome and possibly to defend against viral patho-
gens [17,18,82,93]. Any virus will have evolved in the
context of RNAi and may be subject to suppression by
small RNAs. Indeed, it has become apparent that most
plant viruses and many mammallian viruses encode a
suppressor of RNAi to help counter this potentially detri-
mental mechanism [94-98]. Recent work has also sug-
gested that many viruses produce their own miRNA
[25,26,99,100]. An interesting paper by Triboulet et al
examines the role of Dicer and Drosha HIV-1 infection
[91]. The authors examine the interplay between HIV and
the cellular miRNA pathway by knocking out Dicer and
examining the effects on viral expression. In the absence
of Dicer the virus actually replicates faster. Although Tri-
boulet and colleagues attribute this to alteration in expres-
sion of cellular miRNA that have an antiviral effect, they
do not rule out the possibility that Dicer is acting upon the
viral RNA itself. In this study we provide evidence that that
TAR element found at the 5' end of HIV-1 RNA transcripts
is processed by Dicer to yield a viral miRNA. We provide
further evidence that this miRNA may be supressing virus
replication and propose that it may be involved in main-
taining viral latency.
First, we analyzed the expression of Dicer in cell types rel-
evant to HIV-1 infection. Western blots revealed that
Dicer is expressed in CD4+ T-cells, the primary target of
HIV infection, as well as in HIV-1 infected T-cells and pri-
mary lymphocytes. Interestingly, monocytic cell lines and
primary monocytes isolated from healthy donors
expressed sub-optimal amounts of Dicer and macro-
phages produced much lower levels of Dicer than did T-
cells. We believe this assay to be the first demonstration
that Dicer, a vital component of the RNAi pathway, is sub-
optimaly expressed in monocytes. This finding is intrigu-
ing; as we started this examination with the hypothesis
that RNAi may be involved in the maintenance of latency
in HIV-1 infected CD4+ T-cells. HIV viral latency is a phe-
nomenon unique to T-cells and has not been reported in
cells of the monocyte lineage. That monocytes and macro-
phages express low levels of Dicer lends further credence
to this theory. The discovery that macrophages express
low levels of Dicer likely has important implications for
treatment of HIV-1 with RNAi and our understanding of
the interaction of this virus with the RNAi pathway.
Indeed, at least two papers have demonstrated that
shRNA, which requires cleavage by Dicer, is functional in
macrophages [56,57]. This suggests that the level of Dicer
expression observed after differentiation is likely suffi-
cient to participate in an active RNAi pathway. Further
examination of Dicer expression and activity in mono-
cytes and macrophages will likely improve our under-
standing of the overall regulation of RNAi.
We showed that Dicer, the protein implicated in creation
of miRNA, is capable of binding the HIV-1 TAR RNA ele-
ment. Cellular miRNA are derived from RNA transcripts,
called primary miRNA (pri-miRNA) that fold into long
stem and loop structures. Drosha processes these struc-
tures into short hairpins of approximately 50–60 nucle-
otides in length called pre-miRNA. Pre-miRNA is exported
to the cytoplasm through the action of Exportin-5 and
processed by Dicer into the mature miRNA. The TAR ele-
ment is an RNA structure that bears significant similarity
to pre-miRNA. As such, we reasoned that the excess of TAR
available in the form of short viral transcripts may be
available for Dicer processing. Using biotin-labeled TAR
we were able to pull down Dicer from cell extracts, show-
ing that the TAR structure is indeed recognized by Dicer.
Continuing this line of reasoning we tested the ability of
recombinant Dicer to process TAR RNA into miRNA. In
vitro transcribed TAR, when incubated with rDicer yields
small RNA of the correct size to be miRNA. Incubation of
a battery of mutant TAR structures with Dicer revealed
additional information regarding specificity. Mutations in
the sequence of the stem, the bulge or the terminal loopBMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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did not abrogate Dicer's ability to cleave the TAR RNA.
However, shortening of the stem to approximately 11
nucleotides did prevent Dicer cleavage. These findings are
in agreement with previous studies on the activity of Dicer
[42,58] and provide evidence that mutations in the TAR
sequence are unlikely to help HIV avoid the generation of
miRNA from the TAR element.
In order to confirm our in vitro findings that TAR can be
processed to produce a viral miRNA, we used RNase pro-
tection to probe HIV-1 infected cells lines for the presence
of TAR derived miRNA. RPA revealed that ACH2, an
infected T-cell line, OM10.1, an infected pro-myelocytic
cell line, HLM-1 and primary T-cell blasts infected de novo
with HIV-1 expressed an HIV-1 miRNA derived from the
5' portion of the TAR element (Fig 4). Upon stimulation
of ACH2 and OM10.1 with TSA we noted an increase in
the expression of the viral miRNA. This increase in miRNA
expression during activated transcription may argue
against a role for RNAi in latency. However, during trans-
activation the production of viral RNA increases approxi-
mately 500-fold, while the level of miRNA expression
increases only 2 fold upon stimulation with TSA [72-74].
We believe that the many fold increase in transcription
may easily overcome the slight increase in miRNA abun-
dance.
The study of HIV-1 LTR driven transcription has lead to
the discovery that short viral transcripts can be detected in
cells containing the HIV-1 LTR. Several groups have
shown convincing evidence for the presence of short tran-
scripts isolated from primary peripheral blood mononu-
clear cells [39-41]. These groups isolated resting T-cells
from HIV-1 infected patients and examined the length of
viral RNA in these cells. Analysis of these samples through
RT-PCR indicated the presence of short (somewhere
between 50–100 nucleotides) viral transcripts. Work by
Jeang and colleagues has shown that production of short
transcripts is not due to transcriptional pausing and that
the presence of SV40 T antigen may increase the detecta-
ble levels of short transcripts in cell lines[101,102]. We
propose that the TAR derived miRNA detected by our RPA
is a result of Dicer processing of short TAR-containing
RNA, as these hairpins represent structures similar to cel-
lular pre-miRNA and would be present in the absence of
activated transcription. However, our analysis cannot rule
out the possibility that longer viral RNA containing TAR
and other viral ORFs may contribute to the production of
miRNA after transactivation.
Lastly, we show evidence that a TAR derived miRNA is
able to inhibit LTR-driven gene expression, likely through
homology to the TAR element found in LTR-driven tran-
scripts. Using a luciferase gene driven by the viral LTR we
were able to show that delivery of TAR RNA, but not a TAR
mutant into 293 cells was able to suppress luciferase
expression (Fig. 5). We show that commercially synthe-
sized siRNA based on TAR sequence are capable of induc-
ing similar effects. Furthermore, we show specific
recruitment of HDAC-1 to the LTR by this TAR derived
miRNA, suggesting a role for this miRNA in transcrip-
tional silencing of HIV.
When considering the RNAi pathway in the context of
viral infection there are four possible outcomes to con-
sider: 1) miRNA generated by the cell acts to regulate cel-
lular genes in response to infection, 2) miRNA generated
by the cell acts to suppress viral genes, 3) viral RNA is
processed into miRNA/siRNA and suppress viral gene
expression, and 4) viral RNA is processed into miRNA/
siRNA that suppress cellular gene expression. The role of
RNAi in cellular gene control is an accepted mechanism,
and perhaps the most well studied aspect of the field
[1,3,82]. It is possible that viral infection causes changes
in the expression of endogenous miRNA, but this possi-
bility has only recently begun to be explored. Three recent
papers discuss the possibility that HIV alters expression of
host cell miRNA and show preliminary evidence that this
may be the case [91,103,104]. It has been reported that
cellular miRNA may have significant homology to certain
viruses and that these miRNA serve to protect the cell from
specific pathogens [95]. Interestingly, one group has pre-
dicted that several cellular miRNA posses homology to the
HIV-1 Nef, Vif, Vpr and Vpu genes [50]. Although this pre-
diction has not yet been validated experimentally it does
suggest a role for cellular miRNA in regulating HIV-1 gene
expression. It has also been demonstrated that siRNA or
miRNA generated from viral sequence may be important
in limiting viral replication [17,82,93]. Furthermore, the
discovery that many viruses encode a suppressor of RNAi
suggests that viruses may be under significant pressure
from the RNAi mechanism [94,96,105]. Lastly, it should
be noted that ongoing work in the field has revealed the
presence of viral miRNA expressed by several other viruses
[24-26,99].
It is worth noting that a paper from the Tuschl lab, which
showed evidence of miRNA in members of herpesvirus
family, tested an HIV-1 infected cell line for the presence
of miRNA and found none [24]. This paper used a high-
throughput method to examine RNA extracts for the pres-
ence of short sequences with similarity to known viral
sequence. Although this is a powerful technique for
screening for unknown miRNA it is likely that this
method, which relies on RNA adaptor ligation and subse-
quent sequencing, may be less sensitive than an RNase
protection assay and incapable of detecting low abun-
dance miRNA. We believe our analysis, which used three
infected cell lines as well as infection of primary cells, pro-BMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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vides conclusive evidence for the existence of an HIV-1
derived miRNA.
Conclusion
Our work has demonstrated the existence of an HIV-1
miRNA derived from the TAR RNA sequence. We propose
that short RNA transcripts of approximately 50 to 100
nucleotides in length are processed by Dicer to yield a
viral miRNA. This miRNA may function to suppress viral
transcription, a process we propose to be involved in
latency, or may even alter the expression of cellular genes
through transcriptional or post-transcriptional gene
silencing (Fig. 7). The continued and even increased pro-
duction of viral miRNA after TSA stimulation of latent
cells opens the possibility that this miRNA may also play
a role in altering cellular gene expression during activated
transcription. It should be noted that although we tested
the ability of Dicer to act directly on the TAR element, we
cannot rule out the in vivo involvement of Drosha in
processing the TAR RNA prior to its export to the cyto-
plasm and processing by Dicer. However, regardless of the
specific pathway for the production of this miRNA we
show in vitro evidence for its creation and in vivo detection
of a TAR derived miRNA through RPA. Furthermore, we
have shown the ability of this miRNA to down regulate
expression of viral genes. This finding, coupled with the
detection of HIV-1 miRNA in un-stimulated HIV-1
infected cells suggests a possible role for this miRNA in
maintaining latency. Further work is in progress to eluci-
date the expression patterns of this miRNA and further
investigate the ability of this TAR derived miRNA to influ-
ence both viral and cellular gene expression.
Methods
Cell Culture, transfections and infections
T-cell lines (CEM, Jurkat, Molt4, Hut78, H9), HIV-1
infected T-cell lines (ACH2, J1.1), monocytes (THP-1),
promonocytes (U-937), HIV-1 infected pro-monocytic
cells (U1), infected pro-myelocytes (OM10.1) and human
B-cell lymphoma cell line (BJAB) were grown in RPMI
(Quality Biologicals) supplemented with 10% FBS, 2 mM
L-glutamine and penicillin/streptomycin. 293 human
fibroblasts, HeLa human cervical carcinoma cells and
HeLa cells stably transfected with a Tat deficient HIV-1
(HLM-1) were cultured in DMEM (Quality Biologicals)
supplemented with 10% FBS, 2 mM L-glutamine, penicil-
lin/streptomycin and, in the case of HLM-1, G418.
For transfections, 293 cells were seeded in a 96 well cul-
ture plate at 15,000 cells/well. The following day the cells
were transfected with 100 nanograms luciferase reporter
plasmids and with either siGL2, siTAR1, siTAR2, TAR-WT,
TAR-D, TAR-A or siEGFP (Dharmacon) using Metafectene
(Biontex) lipid reagent (Table 1). Total amount of siRNA
was held constant using siGFP. The underlined areas of
TAR sequence shown in Table 1 are the areas targeted by
siTAR1 and siTAR2.
For infections HIV-1 strain LAV was grown from OM10.1
infected promyelocytes by treatment of the cells with TNF-
α. Virus containing supernatant was harvest, filtered to
remove cells and concentrated by ultra-centrifugation.
PBMCs were cultured in RPMI supplemented with IL-2
and PHA for 48 hours prior to infection. After infection
cells were cultured in RPMI with IL-2.
Isolation of PBMCs
Peripheral blood mononuclear cells were isolated from
healthy donor blood according to standard procedures. In
brief, 10 ml of blood was layered over 5 ml of ficoll and
spun at 1000 × G for 30 minutes with no braking. The
white cell layer was removed and washed twice with PBS.
PBMCs were plated at ~5 × 106 cells/well in a 6-well cul-
ture plate in DMEM with no FBS. Cells were incubated at
Model for the generation and action of HIV-1 TAR derived  miRNA Figure 7
Model for the generation and action of HIV-1 TAR 
derived miRNA. Basal transcription of the HIV-1 LTR pro-
duces short RNA transcripts containing the TAR element. 
These RNA elements are directed to the cytoplasm where 
they are processed by Dicer to yield a viral miRNA. This viral 
miRNA associates with the RISC or RITS complex and 
through homology to sequence contained in the viral RNA, 
as well as the proviral genome, may direct silencing of viral 
gene expression. Alternatively, the viral miRNA may contain 
sufficient homology to mediate silencing of cellular genes. 
Our work identifies a role for Dicer in the generation of an 
HIV-1 miRNA, but we cannot rule out the involvement of 
Drosha in vivo. An alternate pathway for the generation of 
this miRNA is indicated by the dashed arrows. It should be 
noted that the two pathways may generate miRNA with 
slightly different sequence, as cleavage by the Drosha enzyme 
would eliminate some sequence from the base of the stem.BMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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37°C and 5% CO2 for one hour to allow adherence. Lym-
phocyte fraction, including CD4+ T-cells, CD8+ T-cells
and B-cells was aspirated from the adhered monocytes.
Monocytes were washed once with PBS and scraped from
the plate. Lymphocytes and monocytes were then washed
once with PBS and lysed to obtain whole cell extracts.
In vitro transcription of TAR and TAR mutants
T7 expression plasmids for TAR and TAR mutants were
obtained from the laboratory of Dr. Ajit Kumar
(GWUMC) and have been previously described [106]. In
the TAR-A compensatory mutant the basepairs have been
switched (G-C becomes C-G) while the non-paired nucle-
otides were unchanged. In TAR-B the pyrmidine bulge was
deleted (UCU at position 22). TAR-C contains a deletion
in the loop (GGG at position 31). TAR-D contains muta-
tions which shorten the stem region (Fig 3 and Table 1).
For in vitro transcription reactions 1.5 micrograms of each
plasmid was linearized with HindIII (New England
Biolabs), ethanol precipitated and used for in vitro tran-
scription via the MegaScript High Yield Transcription Kit
(Ambion). After transcription TAR RNA was purified on a
2% agarose gel, eluted from the gel with 0.5 M NaAcetate,
1 mM EDTA, 0.2% SDS, and ethanol precipitated before
re-suspension in DEPC treated water.
Biotin-TAR pulldown
One milligram of whole-cell extract from 293, CEM,
ACH2 and BJAB was incubated with 1.5 microgram
biotin-TAR (a gift of Dr. Sergei Nekhai, Howard Univer-
sity, Washington, DC) and RNase inhibitor at 4°C for two
hours. For competition assays, 3.4 micrograms (2.4 fold
excess) of wildtype or mutant TAR was added to the mix-
ture. TAR bound proteins were pulled down by incuba-
tion with streptavidin-sepharose beads (Amersham) at a
30% slurry for 1.5 hours at 4°C. Unbound proteins were
washed three times with TNE-150 +0.1% NP-40. Bound
proteins were denatured from the beads and TAR RNA by
addition of Laemli buffer and heating to 95°C for two
minutes. Proteins were resolved by SDS-PAGE and
detected for Dicer by western blot.
Western blot
Cell extracts and TAR bound protein fractions were
resolved by SDS-PAGE on a 4–20% tris-glycine gel (Invit-
rogen). Proteins were transferred to Immobilon mem-
branes (Millipore) at 200 mA for 2 hours. Membranes
were blocked with PBS 0.1% Tween-20 + 5% BSA. Primary
antibody against either Dicer (AbCam, AB14601) or Actin
(SantaCruz, SC-1615) was incubated with the membrane
in PBS +0.1% Tween-20 at 0.5 ug/ml overnight at 4°C.
Membranes were washed three times with PBS +0.1%
Tween-20 and incubated with HRP-conjugated secondary
antibody for one hour. Presence of secondary antibody
was detected by SuperSignal West Dura Extended Dura-
tion Substrate (Pierce). Luminescence was visualized on a
Kodak 1D image station.
Dicer cleavage
Wildtype and mutant TAR were digested with recom-
binant Dicer (Stratagene) according to the manufacturer's
directions. After cleavage, RNA was resolved on a 6% TBE-
Urea gel and stained with ethidium bromide. Densitome-
try was performed to verify the presence of cleavage prod-
ucts. For each TAR variant intensity of the undigested
input band was set to 100% and the relative intensity of
the region of the gel corresponding to 21 nucleotides was
determined for both Dicer digested and un-digested lanes.
RNase protection assay
Total RNA was extracted from HLM-1, OM10.1, ACH2
and HeLa cells treated or untreated with TSA for 24 hours
using Trizol reagent (Invitrogen).
Radio-labeled RNA probes were prepared by annealing a
DNA oligo containing the T7 promoter sequence to a
complementary oligo containing sequence from the 5'
portion of TAR (Table 1). Annealed template was tran-
scribed using the MaxiScript T7 transcription kit
(Ambion) using α-32P ATP. Following transcription the
37 nucleotide RNA probe was purified by separation on a
15% TBE-Urea poly-acrylamide gel (Invitrogen) followed
by elution and precipitation of the RNA probe.
Presence of a 21 nucleotide HIV derived miRNA was
detected with the RPA III kit (Ambion) as described by the
manufacturer. In brief, 30 microgram of total RNA was
hybridized to 2 × 105 CPM of probe. Hybridized products
were separated on a 15% TBE-Urea gel. Protected probe
was detected by exposure of the gel to a phosphor-imager
cassette.
Luciferase assays
Forty-eight hours after transfection, luciferase activity of
renilla and firefly luciferase was assayed with the DualGlo
Luciferase Assay (Promega). Luminescence was measured
on an EG&G Berthold luminometer. LTR driven firefly
luciferase levels were normalized to CMV driven renilla
luciferase readings. Data shown represents at least three
repeats of each condition.
Chromatin immunoprecipitation
293 cells were transfected with pLTR-Luc and either
siEGFP, siTAR1 or TAR-WT RNA. After 48 hours cells were
pelleted, washed, crosslinked with 1% formaldehyde,
lysed and sonicated to shear DNA to ~1000 bp. Lysate was
immunoprecipitated with 5 micrograms of HDAC-1 anti-
body (Abcam #ab7028) or a control anti-rabbit IgG. PCR
was performed on DNA diluted 1:20 using LTR or luci-
ferase specific primers (Table 1).BMC Molecular Biology 2007, 8:63 http://www.biomedcentral.com/1471-2199/8/63
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To evaluate HDAC recruitment to an integrated HIV-1 LTR
TZMbl cells were used. TZMbl were treated for 7 days with
TSA to remove HDAC-1, then ChIPed for HDAC-1 LTR
after recovery with or without transfection of various
RNAs.
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